BioCentury
ARTICLE | Clinical News

AEGR-733: Preliminary Phase III data

November 10, 2008 8:00 AM UTC

Preliminary data from an ongoing, open-label, Phase III trial in 25 patients showed that AEGR-733 titrated up to 60 mg/day was well tolerated and reduced LDL-C by >50% in the majority of patients that...